Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Open-label rusfertide
Rusfertide · 2 trials · 1 indication
Median hematocrit
Number of phlebotomies
Response is defined as absence of phlebotomy eligibility.
| Arm | Type | Description |
|---|---|---|
| Open-label rusfertide | EXPERIMENTAL | Open-label rusfertide |
| Rusfertide | EXPERIMENTAL | Rusfertide (32 Weeks) - Rusfertide (124 Weeks Open-label) |
| Placebo | EXPERIMENTAL | Placebo (32 Weeks) - Rusfertide (124 Weeks Open-label) |
| Name | Type | Description |
|---|---|---|
| Open-label rusfertide | DRUG | subcutaneous rusfertide |
| Placebo | DRUG | Placebo |
| Rusfertide | DRUG | Experimental drug |
Inclusion Criteria: * Subject who has completed at least 12 months of dosing with rusfertide and successfully completed the end of treatment visit of a previous Phase 2 study of rusfertide. * Subject understands the study procedures, is willing and able to adhere to study requirements and agrees to...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Protagonist Therapeutics, Inc. | PTGX | 2 | PHASE3 | Rusfertide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-3405 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
Rusfertide is an investigational small molecule being developed for the treatment of Polycythemia Vera, a hematologic condition. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with this condition to evaluate its safety and efficacy.
Rusfertide is a peptide-based small molecule, classified under the -tide (peptide) target class. It is being studied for its effects in Polycythemia Vera, a hematologic disorder. The specific molecular target of Rusfertide is not disclosed in the available clinical trial information.
Rusfertide is being developed by Protagonist Therapeutics, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol PTGX. The company is conducting Phase 3 clinical trials to evaluate the drug's safety and efficacy in patients with Polycythemia Vera.
Rusfertide is currently in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The drug is being studied in active clinical trials for the treatment of Polycythemia Vera, with two ongoing Phase 3 studies.
Rusfertide is being evaluated in two active Phase 3 clinical trials. The first, NCT05210790, is a study in patients with Polycythemia Vera with an enrollment of 293 participants across multiple countries. The second, NCT06033586, is a long-term safety study with 46 participants in the United States.
Rusfertide is also known as open-label rusfertide, referring to the drug when administered in an open-label study design. In the clinical trials, rusfertide is being studied in a randomized, double-blind, controlled setting, and the open-label term may refer to a specific phase of the study where blinding is not applied.